Insmed Incorporated (INSM)
| Market Cap | 21.92B -36.1% |
| Revenue (ttm) | 1.14B +185.8% |
| Net Income | -875.31M |
| EPS | -4.09 |
| Shares Out | 218.38M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,412,564 |
| Open | 100.52 |
| Previous Close | 100.48 |
| Day's Range | 99.15 - 101.82 |
| 52-Week Range | 90.39 - 212.75 |
| Beta | 0.82 |
| Analysts | Strong Buy |
| Price Target | 197.74 (+96.97%) |
| Earnings Date | Oct 29, 2026 |
About INSM
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also develops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 ... [Read more]
Financial Performance
In 2025, Insmed's revenue was $606.42 million, an increase of 66.73% compared to the previous year's $363.71 million. Losses were -$1.28 billion, 39.7% more than in 2024.
Financial StatementsAnalyst Summary
According to 24 analysts, the average rating for INSM stock is "Strong Buy." The 12-month stock price target is $197.74, which is an increase of 96.97% from the latest price.
News
Insmed Announces CFO Transition
— Sara Bonstein Will Step Down as CFO on October 30 After Nearly Seven Years of Dedicated Leadership — — Company Reaffirms Full-Year 2026 Financial Guidance — — Company Announces Third-Quarter 2026 Fi...
FDA Grants Priority Review to Insmed's sNDA for ARIKAYCE® (amikacin liposome inhalation suspension) for Treatment of MAC Lung Disease With PDUFA Target Action Date Set for January 28, 2027
—sNDA Under Review for Full Approval Is Based on Positive Results From Phase 3b ENCORE Study— —Full Approval Could Bring ARIKAYCE to Patients Earlier in Their Disease Course and Would Fulfill Post-Mar...
Insmed Expands Community Impact During Fifth Annual Global Day of Good
Company-wide day of service brings together more than 1,350 employees to support over 50 organizations throughout the U.S., Europe, and Japan BRIDGEWATER, N.J., Sept. 16, 2026 /PRNewswire/ -- Insmed I...
Insmed Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
BRINSUPRI's launch has exceeded expectations, with first-year revenue estimates of $1.25–$1.4 billion and peak sales guidance raised above $7 billion. Expansion into COPD/asthma comorbid populations and international markets, especially Japan, are key growth drivers. The pipeline, including TPIP and gene therapies, is advancing, and AI is deeply integrated across operations.
Insmed Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
Peak sales guidance was raised to $14 billion, driven by strong BRINSUPRI and TPIP performance and expanding indications. The BRINSUPRI launch exceeded benchmarks, with rapid patient uptake, high payer approval, and growing market potential. Profitability is expected next year.
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BRIDGEWATER, N.J., Sept. 4, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform...
Insmed to Present Data Across Its Respiratory Portfolio, Including New Late-Breaking ARIKAYCE® (amikacin liposome inhalation suspension) Results From Phase 3b ENCORE Study at the European Respiratory Society Congress 2026
— New Data Explore Efficacy and Safety of BRINSUPRI ® (brensocatib) in Patients With Non-Cystic Fibrosis Bronchiectasis (NCFB) and History of Nontuberculous Mycobacterial (NTM) Lung Disease— —New Rese...
Insmed to Present at September 2026 Investor Conferences
BRIDGEWATER, N.J., Aug. 26, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform...
Insmed Slides: Investor presentation
Insmed has posted slides in relation to its latest quarterly earnings report, which was published on August 24, 2026.
BRINSUPRI® (brensocatib) Approved by Japan's Ministry of Health, Labour and Welfare for the Treatment of Patients With Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease
— First-in-Disease and First-in-Class Therapy Approved in Japan for Patients With Non-Cystic Fibrosis Bronchiectasis (NCFB), a Progressive Disease That Can Lead to Permanent Lung Damage — BRIDGEWATER,...
Insmed Earnings Call Transcript: Q2 2026
Q2 2026 saw record BRINSUPRI growth, with revenue up 49% sequentially and new patient starts exceeding expectations. Full-year guidance for BRINSUPRI was raised to $1.25–$1.4B, and peak sales estimates for key assets increased, while cash flow positivity is expected in 2027.
Insmed Quarterly report: Q2 2026
Insmed has published its Q2 2026 quarterly earnings report on August 6, 2026.
Insmed Earnings release: Q2 2026
Insmed released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Insmed Slides: Q2 2026
Insmed has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 6, 2026.
Insmed Reports Second-Quarter 2026 Financial Results and Provides Business Update
—Total Company Revenues of $425.5 Million for the Second Quarter of 2026— —BRINSUPRI ® (brensocatib) Revenues of $309.2 Million for the Second Quarter of 2026, Reflecting 49% Growth Over the First Qua...
Insmed to Host Second-Quarter 2026 Financial Results Conference Call on Thursday, August 6, 2026
BRIDGEWATER, N.J., July 23, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform...
Insmed Transcript: Study result
The 12-month open-label extension of TPIP in PAH patients showed sustained and clinically meaningful improvements in exercise capacity, cardiac biomarkers, and risk scores, with a favorable safety profile even at high doses. Over 25% achieved asymptomatic status, and 65% reached refined low-risk, supporting TPIP's potential as a leading PAH therapy.
Insmed Press release: Study result
Insmed issued a press release on July 16, 2026, disclosing material business information to investors.
Insmed Slides: Study result
Insmed has posted slides in relation to its latest quarterly earnings report, which was published on July 16, 2026.
Insmed Announces Positive 12-Month Data from the Ongoing Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Patients with Pulmonary Arterial Hypertension
– 12-Month Data Demonstrated Sustained Improvement with TPIP Across All Secondary Efficacy Measures Including Reduction in Mortality Risk Status by REVEAL Lite 2.0– –Placebo Crossed Group Demonstrated...
EMBARC Announces Its Intention to Collaborate with Insmed on Landmark Interventional Study Evaluating Disease Modification Potential of Brensocatib in Bronchiectasis
Hannover, Germany, June 25, 2026 (GLOBE NEWSWIRE) -- EMBARC Announces Its Intention to Collaborate with Insmed on Landmark Interventional Study Evaluating Disease Modification Potential of Brensocatib...
Insmed Appoints Samuele Butera as Senior Vice President, General Manager, Global Respiratory
BRIDGEWATER, N.J., June 23, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform...
Insmed Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
BRINSUPRI’s launch is exceeding benchmarks, with strong physician engagement and a robust support program driving persistence. Expansion into comorbid populations and upcoming launches in Japan are expected to fuel further growth, while a diverse pipeline and prudent financial strategy position the company for sustained success.
Insmed to Present at the 2026 Goldman Sachs Annual Global Healthcare Conference
BRIDGEWATER, N.J., May 27, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform ...
Insmed Transcript: RBC Capital Markets Global Healthcare Conference 2026
Strong quarterly growth and operational execution support a $1B+ revenue target, with high payer approval and patient retention. Market expansion is driven by education, new patient identification, and robust pipeline progress, including ARIKAYCE and TPIP.